QQ客服 官方微博 反馈留言

浏览/检索结果: 共12条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study 期刊论文 CANCER MEDICINE, 2022 作者:  Yu, Xiaoqing;  Si, Jinfei;  Wei, Jingwen;  Wang, Yanling;  Sun, Yan 收藏  |  浏览/下载：16/0  |  提交时间：2022/12/23 EGFR-TKIs  non-small cell lung cancer (NSCLC)  real-world study  survival outcome   A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17 作者:  Lu, S.;  Zhang, Y.;  Zhang, G.;  Zhou, J.;  Cang, S. 收藏  |  浏览/下载：19/0  |  提交时间：2022/12/23 third-generation EGFR-TKI  befotertinib  T790M   HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib 期刊论文 ANNALS OF PALLIATIVE MEDICINE, 2022, 卷号: 11 作者:  Fan, Ying;  Qin, Jing;  Han, Na;  Lu, Hongyang 收藏  |  浏览/下载：14/0  |  提交时间：2022/12/23 Leptomeningeal metastasis (LM)  cerebrospinal fluid  HER2 exon 20 insertion mutations  poziotinib  case report   LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang 收藏  |  浏览/下载：58/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Zou, Hui-xi;  Zhang, Yu-feng;  Zhong, Da-fang;  Jiang, Yong;  Liu, Fei 收藏  |  浏览/下载：17/0  |  提交时间：2022/01/04 furmonertinib  autoinduction  food effect  alkaline phosphatase  body weight  pharmacokinetics  modeling and simulation  NSCLC   Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu 收藏  |  浏览/下载：18/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity 期刊论文 JOURNAL OF CONTROLLED RELEASE, 2021, 卷号: 329, 页码: 1249-1261 作者:  Zhao, Pengfei;  Zhang, Jiaxin;  Wu, Aihua;  Zhang, Meng;  Zhao, Yuge 收藏  |  浏览/下载：107/0  |  提交时间：2021/05/24 Brain targeting delivery  Tumor-associated macrophage  Osimertinib resistance  Brain metastasis  Innate immunity  Combination therapy   Discovery of a novel third generation EGFR TKI and identification of its potential mechanism of resistance 期刊论文 CANCER RESEARCH, 2019, 卷号: 79, 期号: 13, 页码: 2 作者:  Zhang, Tao;  Qu, Rong;  Chen, Chengbin;  Tong, Linjiang;  Feng, Fang 收藏  |  浏览/下载：4/0  |  提交时间：2020/07/01 Synthesis and Biological Evaluation of Oxopyrido[2,3-d] Pyrimidine-7-ones Derivatives as Covalent L85812/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors 期刊论文 LETTERS IN DRUG DESIGN & DISCOVERY, 2019, 卷号: 16, 期号: 8, 页码: 826-834 作者:  Niu, Ao;  Wang, Yang;  Yang, Yushe;  Wei, Jianhai;  Ding, Jian 收藏  |  浏览/下载：12/0  |  提交时间：2020/07/01 Non-small cell lung cancer  irreversible inhibitors  EGFR(T79014)( )mutant  anti-tumor  xenograft model  cell proliferation   Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib 期刊论文 CLINICAL CANCER RESEARCH, 2018, 卷号: 24, 期号: 11, 页码: 2594-2604 作者:  Liu, Shengwu;  Hai, Josephine;  Wang, Xiaoen;  Quinn, Max M.;  Gao, Peng 收藏  |  浏览/下载：81/0  |  提交时间：2019/04/28 Receptor Tyrosine Kinase  Phase-ii Trial  Bromodomain Inhibition  Combination Therapy  Acquired-resistance  Domain Mutations  Bet Bromodomains  Breast-cancer  Egfr  Mutant